Kristina Burow is a Managing Director at ARCH Venture Partners, which she joined in 2002 after being an early employee at the Genomics Institute of the Novartis Research Foundation, where she directed Chemistry Operations and worked in business development creating company spinouts. She is a co-founder and director of Neumora Therapeutics and a director of Scholar Rock, Boundless Bio, Mirador Therapeutics, Architect Therapeutics, Autobahn Therapeutics, Pretzel Therapeutics, Tenvie Therapeutics, Treeline Biosciences and Magnet Biomedicine. She previously co-founded and served as a director of Receptos, Orbital Therapeutics, Vividion Therapeutics and Metsera, and was a director of Beam Therapeutics, Gossamer Bio and Vir Biotechnology. She holds a B.S. in Chemistry from the University of California, Berkeley, an M.A. in Chemistry from Columbia University and an M.B.A. from the University of Chicago.
Education
B.S. Chemistry, University of California, Berkeley
M.A. Chemistry, Columbia University
M.B.A., University of Chicago
Previous Experience
Genomics Institute of the Novartis Research Foundation (GNF), early employee; directed Chemistry Operations and worked in Business Development creating company spinouts
Notable Investments
Neumora Therapeutics NMRAScholar Rock SRRKBoundless Bio BOLDMirador TherapeuticsTreeline BiosciencesAutobahn TherapeuticsPretzel TherapeuticsMagnet BiomedicineReceptosMetseraVividion TherapeuticsVir Biotechnology VIRBeam Therapeutics BEAMGossamer Bio GOSS
Board Seats
Neumora Therapeutics
Scholar Rock
Boundless Bio
Mirador Therapeutics
Architect Therapeutics
Autobahn Therapeutics
Pretzel Therapeutics
Tenvie Therapeutics
Treeline Biosciences
Magnet Biomedicine
Career Timeline
null
Was an early employee of the Genomics Institute of the Novartis Research Foundation, directing Chemistry Operations and creating company spinouts.
2002
Joined ARCH Venture Partners.
null
Co-founded Receptos, which was acquired by Celgene.
null
Co-founded Neumora Therapeutics and serves as a director.